Peng Wang1,2, Jie Xu1, Zhiling Hou3, Fangfang Wang4, Yingli Song1, Jiao Wang1, Hui Zhu1, Hongbo Jin1. 1. Department of Physiology, College of Basic Medical Sciences, Harbin Medical University, Harbin, China. 2. Department of Physiology, College of Basic Medical Sciences, Harbin Medical University-Daqing, Daqing, China. 3. Department of Emergency Surgery, The First Affiliated Hospital of Jiamusi University, Jiamusi, China. 4. Department of Pathophysiology, College of Basic Medical Sciences, Jiamusi University, Jiamusi, China.
Abstract
OBJECTIVES: Pulmonary arterial hypertension (PAH) is a fast progressing vascular disease characterized by uncontrolled cell proliferation of pulmonary artery smooth muscle cells (PASMCs). Some studies have suggested that PAH and cancers share an apoptosis-resistant state, featuring excessive cell proliferation. The miR-34 family consists of tumour-suppressive miRNAs, and its reduced expression has been reported in numerous cancers; however, its role in hypoxia-induced PAH has not been previously studied. MATERIALS AND METHODS: miR-34 family expression was evaluated in a rat model with hypoxia and in cultured hypoxic PASMCs, using real-time quantitative PCR (RT-qPCR). Function of miR-34 family was assessed by transfecting miR-34 mimics and inhibitors. Dual luciferase reporter gene assays, RT-qPCR and Western blotting were performed to validate target genes of miR-34. RESULTS: Significant down-regulation of miR-34a in hypoxic lung tissue, pulmonary artery and PASMCs was identified and then effects of miR-34a in modulating cell proliferation in human pulmonary artery smooth muscle cells (hPASMCs) was investigated in vitro. Reduction of miR-34a levels in hPASMCs caused increased proliferation and these effects were reversed by overexpression of miR-34a. miR-34a overexpression down-regulated platelet-derived growth factor receptor alpha (PDGFRA) expression, which is a key factor in PAH development. These results suggest that miR-34a is a potential regulator of proliferation in PASMCs, and that it could be used as a novel treatment strategy in PAH.
OBJECTIVES:Pulmonary arterial hypertension (PAH) is a fast progressing vascular disease characterized by uncontrolled cell proliferation of pulmonary artery smooth muscle cells (PASMCs). Some studies have suggested that PAH and cancers share an apoptosis-resistant state, featuring excessive cell proliferation. The miR-34 family consists of tumour-suppressive miRNAs, and its reduced expression has been reported in numerous cancers; however, its role in hypoxia-induced PAH has not been previously studied. MATERIALS AND METHODS:miR-34 family expression was evaluated in a rat model with hypoxia and in cultured hypoxic PASMCs, using real-time quantitative PCR (RT-qPCR). Function of miR-34 family was assessed by transfecting miR-34 mimics and inhibitors. Dual luciferase reporter gene assays, RT-qPCR and Western blotting were performed to validate target genes of miR-34. RESULTS: Significant down-regulation of miR-34a in hypoxic lung tissue, pulmonary artery and PASMCs was identified and then effects of miR-34a in modulating cell proliferation in human pulmonary artery smooth muscle cells (hPASMCs) was investigated in vitro. Reduction of miR-34a levels in hPASMCs caused increased proliferation and these effects were reversed by overexpression of miR-34a. miR-34a overexpression down-regulated platelet-derived growth factor receptor alpha (PDGFRA) expression, which is a key factor in PAH development. These results suggest that miR-34a is a potential regulator of proliferation in PASMCs, and that it could be used as a novel treatment strategy in PAH.
Authors: Y Sekkach; F Mekouar; M Jira; M Elqatni; N Elomri; J Fatihi; M Badaoui; S Hammi; J Smaali; A El Khattabi; T Amezyane; A Abouzahir; D Ghafir Journal: Ann Pharm Fr Date: 2011-09-08
Authors: Matthias Brock; Michelle Trenkmann; Renate E Gay; Beat A Michel; Steffen Gay; Manuel Fischler; Silvia Ulrich; Rudolf Speich; Lars C Huber Journal: Circ Res Date: 2009-04-23 Impact factor: 17.367
Authors: Sebastien Bonnet; Gael Rochefort; Gopinath Sutendra; Stephen L Archer; Alois Haromy; Linda Webster; Kyoko Hashimoto; Sandra N Bonnet; Evangelos D Michelakis Journal: Proc Natl Acad Sci U S A Date: 2007-06-27 Impact factor: 11.205
Authors: Charles A Ducsay; Ravi Goyal; William J Pearce; Sean Wilson; Xiang-Qun Hu; Lubo Zhang Journal: Physiol Rev Date: 2018-07-01 Impact factor: 37.312
Authors: Kuang-Hueih Chen; Asish Dasgupta; Jianhui Lin; François Potus; Sébastien Bonnet; James Iremonger; Jennifer Fu; Jeffrey Mewburn; Danchen Wu; Kimberly Dunham-Snary; Anne L Theilmann; Zhi-Cheng Jing; Charles Hindmarch; Mark L Ormiston; Allan Lawrie; Stephen L Archer Journal: Circulation Date: 2018-02-05 Impact factor: 29.690